— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — &md...
Intas Pharmaceuticals announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive op...
AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommen...
Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and o...
Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opin...
New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring -...
Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, announces that the U...
– Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromata...
Valneva SE , a specialty vaccine company, announced the submission of label extension applications to the European Medicines Agency (EMA) and Hea...
Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China ZERVIATE® launch in China wil...
BeiGene, a global oncology company, announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for t...
Altamira Therapeutics announces the extension of its exclusive license with Nuance Pharma to cover Singapore, Malaysia, Thailand, Philippines, Indonesia,...
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance gene...
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's off...
© 2025 Biopharma Boardroom. All Rights Reserved.
